sclareol has been researched along with Disease Models, Animal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hassan, ZM; Noori, S; Salehian, O | 1 |
| Huang, Y; Santoso, MB; Wu, LD; Zhong, Y | 1 |
2 other study(ies) available for sclareol and Disease Models, Animal
| Article | Year |
|---|---|
Sclareol reduces CD4+ CD25+ FoxP3+ Treg cells in a breast cancer model in vivo.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Breast Neoplasms; Cancer Vaccines; CD4 Antigens; Cell Proliferation; Disease Models, Animal; Diterpenes; Female; Forkhead Transcription Factors; Humans; Injections, Intraperitoneal; Interferon-gamma; Interleukin-2 Receptor alpha Subunit; Interleukin-4; K562 Cells; Mice; Mice, Inbred BALB C; Salvia; T-Lymphocytes, Regulatory; Tumor Burden | 2013 |
Sclareol exerts anti-osteoarthritic activities in interleukin-1β-induced rabbit chondrocytes and a rabbit osteoarthritis model.
Topics: Animals; Anti-Inflammatory Agents; Cartilage, Articular; Cells, Cultured; Chondrocytes; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Gene Expression Regulation; Humans; Injections, Intra-Articular; Interleukin-1beta; Joints; Matrix Metalloproteinases; Nitric Oxide; Nitric Oxide Synthase Type II; Osteoarthritis; Rabbits; RNA, Messenger; Signal Transduction; Tissue Inhibitor of Metalloproteinase-1 | 2015 |